Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC-Reference-Cited by-同舟云学术

Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC

Published:2019-02-11 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Gao Qun,Wang Shumin,Chen Xinfeng,Cheng Shaoyan,Zhang Zhen,Li Feng,Huang Lan,Yang Yang,Zhou Bin,Yue Dongli,Wang Dan,Cao Ling,Maimela Nomathamsanqa Resegofetse,Zhang Bin,Yu Jane,Wang Liping,Zhang Yi^ORCID

Funder

National Natural Science Foundation of China

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0511-6.pdf

Reference46 articles.

1. Rigas R. J. Taxane-platinum combinations in advanced non-small cell lung Cancer:a review. Oncologist. 2004;9:16–23.

2. Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, et al. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol. 2015;26:1401–8.

3. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624–36.

4. Durm G, Hanna N. Second-line chemotherapy and beyond for non-small cell lung Cancer. Hematol Oncol Clin North Am. 2017;31:71–81.

5. Shukuya T, Ko R, Mori K, Kato M, Yagishita S, Kanemaru R, Honma Y, Shibayama R, Koyama R, Shimada N, et al. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents. Cancer Chemother Pharmacol. 2015;76:771–6.

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in and prospects of immunotherapy for prostate cancer;Cancer Letters;2024-10

2. Overexpression of serum HMGB1 and IDO in esophageal squamous cell carcinoma patients: potential clinical auxiliary diagnostic markers and immunotherapeutic targets;Frontiers in Oncology;2024-09-09

3. Carrageenan-ferrocene-eicosapentaenoic acid composite hydrogel induce ferroptosis and apoptosis for anti-tumor recurrence and metastasis;International Journal of Biological Macromolecules;2024-09

4. Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology‐based strategies for enhanced CAR T/NK cell therapy;Bioengineering & Translational Medicine;2024-08-31

5. Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity;Cellular Oncology;2024-08-14